Peer-reviewed veterinary case report
New live vaccine protects dogs from H3N8 and H3N2 flu viruses
By Rodriguez, Laura et al.·Published in Vaccine·2017·Department of Microbiology and Immunology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses.
- Species:
- dog
Plain-English summary
A new bivalent live-attenuated influenza vaccine has been developed to protect dogs from two strains of canine influenza viruses (CIVs), H3N8 and H3N2, which cause respiratory illness. Current vaccines are inactivated and not very effective, but this new vaccine showed better protection in tests with mice after just one dose given through the nose. It also triggered a stronger immune response compared to the older vaccines. This bivalent vaccine could significantly improve the prevention of canine influenza in dogs.
People also search for: dog flu vaccine · canine influenza symptoms · H3N2 vaccine for dogs
Abstract
Canine influenza viruses (CIVs) cause a contagious respiratory disease in dogs. CIV subtypes include H3N8, which originated from the transfer of H3N8 equine influenza virus (EIV) to dogs; and the H3N2, which is an avian-origin virus adapted to infect dogs. Only inactivated influenza vaccines (IIVs) are currently available against the different CIV subtypes. However, the efficacy of these CIV IIVs is not optimal and improved vaccines are necessary for the efficient prevention of disease caused by CIVs in dogs. Since live-attenuated influenza vaccines (LAIVs) induce better immunogenicity and protection efficacy than IIVs, we have combined our previously described H3N8 and H3N2 CIV LAIVs to create a bivalent vaccine against both CIV subtypes. Our findings show that, in a mouse model of infection, the bivalent CIV LAIV is safe and able to induce, upon a single intranasal immunization, better protection than that induced by a bivalent CIV IIV against subsequent challenge with H3N8 or H3N2 CIVs. These protection results also correlated with the ability of the bivalent CIV LAIV to induce better humoral immune responses. This is the first description of a bivalent LAIV for the control and prevention of H3N8 and H3N2 CIV infections in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28709557/